Smoking cessation for people with chronic obstructive pulmonary disease

Eerd, Eva Anne Marije van; Meer, Regina M van der; Schayck, Onno C. P. van; Kotz, Daniel

doi:10.1002/14651858.cd010744.pub2

Cited by 109 publications

(124 citation statements)

References 113 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…It must be noted that psychological counselling in the studies by Tashkin et al and Jiménez-Ruiz et al were intensive, while in our study the patients received brief counselling. The need for intense psychological counselling in smokers with COPD in order to increase smoking cessation rates has been highlighted in a recent meta-analysis [4]. Probably, this could be a reason for the low abstinence rates found in this study.…”

Section: Original Articlementioning

confidence: 74%

“…The schedule of visits for each participant were as follows: at baseline, at 2,4,8,12,16,20,24 weeks and additionally at 9 and 12 months. Also, there were two telephone calls at 8 th and 20 th weeks.…”

Section: Procedures and Interventionsmentioning

confidence: 99%

“…Despite this, a significant percentage of these patients continue smoking [3]. A recent meta-analysis reports that the most effective treatment to help COPD smokers quit is a combination of medication and intensive psychological counselling [4]. Nicotine Replacement Therapy (NRT), bupropion and varenicline have been shown to be effective and safe in helping patients with COPD quit [4].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Varenicline in smokers with severe or very severe COPD after 24 weeks of treatment. A descriptive analysis: VALUE study

Jiménez-Ruíz

Rueda²,

Muñiz

et al. 2017

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

A large number of COPD patients are smokers. The particular characteristics of this group as well as their need to quit usually require psychological counselling and pharmacological treatment to achieve abstinence and, often, intensively. The main objective of the study was to evaluate the effectiveness of varenicline after 24 weeks of treatment, with continuous abstinence between weeks 9 and 24, in patients with severe or very severe COPD. This study was a post-authorization, open label, observational study of prospective follow-up. Patients included were smokers with severe or very severe COPD criteria who were treated with varenicline for 24 weeks, i.e. with a 12-week extension over the usual treatment. The outcomes in the population of subjects completing 24 weeks of follow-up were at week 24: continuous abstinence 36.8%, 7 days point prevalence abstinence 65.7%, and continuous smoking 31.5%. The outcomes in the intention-to-treat population included at baseline were: continuous abstinence 17.7% of patients, 7 days point prevalence abstinence 31.6%, continuous smoking 15.1% and not valid/unknown 51.8%. The mean CAT score at week 24 was 15 and reduction from the baseline was 3.77 (paired t-test, p<0.01). The most common adverse events reported were nausea, vivid dreams, stomach ache, insomnia, headache and vomiting. Patients included in VALUE were active smokers despite all of them had a severe COPD which suggests a very high degree of dependence. Although the study do not allow to infer the results to the global population of smokers with severe COPD, the outcomes have shown that, at 24 weeks follow up 36.8% of the patients were successful in quitting but from 79 patients enrolled initially only 17.7% quit.

show abstract

Section: Original Articlementioning

confidence: 74%

Section: Procedures and Interventionsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Varenicline in smokers with severe or very severe COPD after 24 weeks of treatment. A descriptive analysis: VALUE study

Jiménez-Ruíz

Rueda²,

Muñiz

et al. 2017

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

show abstract

“…Participation in a smoking cessation program compared to non-participation was shown to significantly decrease self-reported phlegm and significantly less number of days hospitalized for COPD [16]. In a meta-analysis including four studies with 1,540 participants, it was found that a combination of behavioral treatment and pharmacotherapy is effective in helping smokers affected by COPD to quit smoking [17]. …”

Section: Introductionmentioning

confidence: 99%

“…A written care plan gives the patient the opportunity to administer adequate medication for early onset of symptoms. A care plan could also include recommendations for diet and physical activity [17]. Patient education and smoking cessation programs are recommended for patients with COPD to reduce the number of exacerbations and hospitalization, but the effect of the programs has yet to be explored in a larger sample.…”

Section: Introductionmentioning

confidence: 99%

Influences of patient education on exacerbations and hospital admissions in patients with COPD – a longitudinal national register study

Henoch

Ekberg-Jansson²

2018

European Clinical Respiratory Journal

View full text Add to dashboard Cite

Introduction: Chronic obstructive pulmonary disease (COPD) contributes to impaired health-related quality of life (HRQoL). Patient education and smoking cessation programs are recommended to reduce the number of exacerbations and hospitalizations, but the effects of such programs have yet to be explored in larger samples. Objective: The aim was to explore the longitudinal effects of patient education and smoking cessation programs on exacerbations and hospital admissions in patients with COPD. Design: This is a register study where data from the Swedish National Airway Register, including 20,666 patients with COPD, were used. Baseline measures of demographic, disease-related, and patient-reported variables were compared with a follow-up, 10–30 months after baseline. Descriptive statistics and changes between baseline and follow-up were calculated. Results: Comparing those not participating in education programs to those who did, HRQoL deteriorated significantly between baseline and follow-up in non-participants; there was no change in either exacerbations or hospitalizations in either group; there was a significant difference in baseline HRQoL between the two, and, when controlling for this, there was no significant change (p = 0.73). Patients who participated in smoking cessation programs were younger than the non-participants; mean 66.0 (standard deviations (SD) 7.8) vs. mean 68.1 (SD 8.8), p = 0.006. Among participants in smoking cessation programs, the proportion with continued smoking decreased significantly, from 76% to 66%, p < 0.001. Exacerbations at follow-up were predicted by FEV1% of predicted value and exacerbations at baseline. Hospital admissions at follow-up were predicted by baseline FEV1% of predicted value and exacerbations at baseline. Conclusions: To prevent exacerbations and hospital admissions, treatment and prevention must be prioritized in COPD care. Patient education and smoking cessation programs are beneficial, but there is a need to combine them with other interventions.

show abstract

Effect of Long-term Nicotine Replacement Therapy vs Standard Smoking Cessation for Smokers With Chronic Lung Disease

et al. 2018

View full text Add to dashboard Cite

Key Points Question Compared with standard cessation approaches, can long-term nicotine replacement therapy lead to higher rates of cessation or reductions in carcinogen exposure among smokers with chronic obstructive pulmonary disease? Findings In this randomized clinical trial of 398 smokers with chronic obstructive pulmonary disease, 23 of 197 (11.7%) receiving a standard smoking cessation intervention had quit at 12 months, compared with 24 of 197 (12.2%) receiving long-term nicotine replacement therapy. Both groups had comparable reductions in carcinogen and smoke exposure. Meaning Long-term nicotine replacement therapy provides an option for smokers with chronic obstructive pulmonary disease but does not result in greater rates of cessation or harm reduction.

show abstract

Smoking cessation for people with chronic obstructive pulmonary disease

Cited by 109 publications

References 113 publications

Varenicline in smokers with severe or very severe COPD after 24 weeks of treatment. A descriptive analysis: VALUE study

Varenicline in smokers with severe or very severe COPD after 24 weeks of treatment. A descriptive analysis: VALUE study

Influences of patient education on exacerbations and hospital admissions in patients with COPD – a longitudinal national register study

Effect of Long-term Nicotine Replacement Therapy vs Standard Smoking Cessation for Smokers With Chronic Lung Disease

Contact Info

Product

Resources

About